Maxime Ranger

Maxime Ranger is a seasoned executive with extensive experience in the biotech and pharmaceutical industries, currently serving as the Chief Executive Officer at Neurenati, focusing on therapeutic options for Hirschsprung disease. As Cofounder and CEO of Numbio Therapeutics, Ranger is involved in developing treatments for tau-related neuropathies, with a focus on ophthalmology. In addition, Ranger holds several advisory roles, including Senior Business/Scientific Advisor at Néolys Pharma, and has a consultancy role at Gestion MRIM Inc. Ranger has also contributed to academia as an Adjunct Professor at Université de Montréal and has served in leadership capacities at various organizations, including giiant pharma inc. and Théâtre Denise-Pelletier. With postdoctoral and advanced degrees in Material Sciences, Drug Delivery, and Polymer Chemistry, Ranger combines a strong scientific background with a solid business acumen.